AbbVie (ABBV) closed at $249.91 in the latest trading session, marking a -1.12% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.81% for the day. At the same time, the Dow added 0.27%, and the tech-heavy Nasdaq gained 1.3%.
Heading into today, shares of the drugmaker had gained 12.35% over the past month, outpacing the Medical sector's gain of 7% and the S&P 500's gain of 1.13%.
Analysts and investors alike will be keeping a close eye on the performance of AbbVie in its upcoming earnings disclosure. The company's earnings report is set to go public on July 31, 2026. It is anticipated that the company will report an EPS of $3.76, marking a 26.6% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $16.79 billion, up 8.86% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of $14.27 per share and revenue of $67.32 billion, which would represent changes of +42.7% and +10.07%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for AbbVie. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.33% fall in the Zacks Consensus EPS estimate. AbbVie is currently a Zacks Rank #3 (Hold).
In the context of valuation, AbbVie is at present trading with a Forward P/E ratio of 17.72. This indicates a premium in contrast to its industry's Forward P/E of 15.87.
We can also see that ABBV currently has a PEG ratio of 0.83. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. ABBV's industry had an average PEG ratio of 2.67 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 198, finds itself in the bottom 20% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).